Abstract
Repeated administration of l-asparaginase leads to the development of specific antibodies and hypersensitivity reactions. The aim of the study was to evaluate a possible cross-reaction of anti-asparaginase antibodies, developed against the native E. coli l-asparaginase (Asparaginase Medac), with other preparations of the enzyme. Sixteen patients with acute lymphoblastic leukemia, in whom in the reinduction phase of treatment hypersensitivity against l-asparaginase was observed and/or the presence of anti-asparaginase antibodies was established were recruited for the present study. Ten out of 16 tested sera showed cross-immunoreactivity to PEG-asparaginase, while no reactivity to l-asparaginase derived from Erwinia chrysantemi was observed. Since cross-reacting antibodies were also found in sera of patients with no overt allergic reaction, l-asparaginase may undergo silent inactivation during the reinduction phase of therapy. This finding is of clinical importance with regard to appropriate dosage and necessitates careful enzyme activity monitoring in all patients undergoing repeated treatment with various l-asparaginase preparations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Narta UK, Kanwar SS, Azmi W (2007) Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 61:208–221
Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, Benoit Y, Robert A, Manel AM, Vilmer E, Otten J, Philippe N (2002) Comparison of Echerichia coli-asparaginase with Erwinia-asparaginase in the treatment of acute lymphoblastic leukemia: results of a randomized European Organisation for Research and Treatment of Cancer–Children’s Leukemia Group phase 3 trial. Blood 99:2734–2739
Müller HJ, Boos J (1998) Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28:97–113
Pui CH (1995) Childhood leukemia. N Engl J Med 332:1618–1630
Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettingrer AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neqlia J, Reaman G, Holcenberg JS, Stork L (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group Study. Blood 99:1986–1994
Broome JD (1968) Factors which may influence the effectiveness of l-asparaginase as tumor inhibitors. Br J Cancer 22:595–602
Abuchowski A, Kazo GM, Verhoest CR Jr, Van Es T, Kafkevitz D, Nuci ML, Viau AT, Davis FF (1984) Cancer therapy with chemically modified enzymes. I Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 7:175–186
Cheung NK, Chau IY, Coccia PF (1986) Antibody response to Escherichia coli l-asparaginase: prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 8:99–104
Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang P, Pui CH, Relling MV (1998) Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12:1527–1533
Asselin BL, Whithin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparation. J Clin Oncol 11:1780–1786
Kamisaki Y, Wada H, Yagura T, Matsushimi A, Inada Y (1981) Reduction in immunogenecity and clearence rate of Echerichia coli l-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 216:410–414
Yashimoto T, Nishimura H, Saito Y (1986) Characterization of PEG modified l-asparaginase from E. coli and its application to the therapy of leukemia. Jpn J Cancer Res 77:1264–1271
Zalewska-Szewczyk B, Andrzejewski W, Bodalski J (2004) Development of anti-asparaginase antibodies in childhood lymphoblastic leukemia. Pediatr Blood Cancer 43:600–602
Ettinger LJ, Kurtzberg J, Voute PA (1995) An open-label, multicenter study of polyethylene glycol l-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 75:1176–1181
Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, Steinherz P, Cohen LJ, Siegel SE, Avramis VI (2004) Children’s Cancer Group StudyAsparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia. J Pediatr Hematol Oncol 26:217–226
Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, Hak LJ (2003) Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17:1583–1588
Müller HJ, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schütz V, Henze G, Casimiro da Palma J, Ritter J, Pinheiro JP, Winkelhorst M, Boos J (2000) Pegylated asparaginase (Oncaspar™) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 110:379–384
Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Muller HJ, Schmiegelow K, Carlsen NT (2002) Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 38:310–316
Acknowledgments
Supported by National Health Committee, grant No 3 P05E 030 22 and No 2P05E 020 29.
Conflict of interest statement
The authors declare that they have no conflict of interest related to the publication of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zalewska-Szewczyk, B., Gach, A., Wyka, K. et al. The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations. Clin Exp Med 9, 113–116 (2009). https://doi.org/10.1007/s10238-008-0026-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-008-0026-9